Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma
Artikel i vetenskaplig tidskrift, 2018

Objective: In clinical practise, prognostication of endometrial cancer is based on clinicopathological risk factors. The use of immunohistochemistry-based markers as prognostic tools is generally not recommended and a systematic analysis of their utility as a panel is lacking. We evaluated whether an immunohistochemical marker panel could reliably assess endometrioid endometrial cancer (EEC) outcome independent of clinicopathological information. Methods: A cohort of 306 EEC specimens was profiled using tissue microarray (TMA). Cost- and time-efficient immunohistochemical analysis of well-established tissue biomarkers (ER, PR, HER2, Ki-67, MLH1 and p53) and two new biomarkers (L1CAM and ASRGL1) was carried out. Statistical modelling with embedded variable selection was applied on the staining results to identify minimal prognostic panels with maximal prognostic accuracy without compromising generalizability. Results: A panel including p53 and ASRGL1 immunohistochemistry was identified as the most accurate predictor of relapse-free and disease-specific survival. Within this panel, patients were allocated into high- (5.9%), intermediate- (29.5%) and low- (64.6%) risk groups where high-risk patients had a 30-fold risk (P < 0.001) of dying of EEC compared to the low-risk group. Conclusions: P53 and ASRGL1 immunoprofiling stratifies EEC patients into three risk groups with significantly different outcomes. This simple and easily applicable panel could provide a useful tool in EEC risk stratification and guiding the allocation of treatment modalities.

Risk stratification

Endometrial cancer

Prognostic

p53

Modelling

ASRGL1

Författare

Jutta Huvila

Turun Yliopisto

Teemu D. Laajala

Helsingin Yliopisto

Turun Yliopisto

P. H. Edqvist

Uppsala universitet

Adil Mardinoglu

Chalmers, Biologi och bioteknik, Systembiologi

Kungliga Tekniska Högskolan (KTH)

Lauri Talve

Turun Yliopisto

F. Ponten

Uppsala universitet

Seija Grénman

Turun Yliopisto

Olli Carpén

Helsingin Yliopisto

Turun Yliopisto

Finland HUSLAB

Tero Aittokallio

Turun Yliopisto

Helsingin Yliopisto

Annika Auranen

Tampereen Yliopisto

Gynecologic Oncology

0090-8258 (ISSN) 1095-6859 (eISSN)

Vol. 149 1 173-180

Ämneskategorier

Klinisk laboratoriemedicin

Urologi och njurmedicin

Cancer och onkologi

DOI

10.1016/j.ygyno.2018.02.016